Detalles de la búsqueda
1.
Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
J Urol
; 206(6): 1420-1429, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34293915
2.
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
Arterioscler Thromb Vasc Biol
; 38(4): 953-963, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29437574
3.
Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.
J Thromb Thrombolysis
; 45(4): 469-476, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29582212
4.
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Circulation
; 134(24): 1918-1930, 2016 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27881559
5.
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.
Am Heart J
; 180: 22-8, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27659879
6.
CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.
Arterioscler Thromb Vasc Biol
; 34(9): 2106-14, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24969776
7.
Preserving Well-being in Patients With Advanced and Late Prostate Cancer.
Urology
; 155: 199-209, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33373704
8.
Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
Curr Med Res Opin
; 37(4): 609-622, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33476184
9.
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.
J Clin Pharmacol
; 59(3): 427-436, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30452776
10.
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.
Clin Pharmacol Drug Dev
; 8(5): 628-636, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30240132
11.
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
J Am Heart Assoc
; 4(8): e002171, 2015 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-26307570
12.
A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.
J Clin Pharmacol
; 54(3): 301-10, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24122814
13.
Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.
Drugs R D
; 13(1): 17-28, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23322528
14.
Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study.
Clin Ther
; 32(12): 2074-87, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21118743
15.
Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.
Cancer Chemother Pharmacol
; 66(6): 1039-49, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20140617
16.
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
Cancer Chemother Pharmacol
; 66(2): 345-56, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19911123
Resultados
1 -
16
de 16
1
Próxima >
>>